WBI Investments LLC Acquires 9,731 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

WBI Investments LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 50.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 29,146 shares of the biopharmaceutical company's stock after buying an additional 9,731 shares during the period. WBI Investments LLC's holdings in Gilead Sciences were worth $2,692,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank bought a new position in shares of Gilead Sciences in the 4th quarter worth $1,789,254,000. FMR LLC boosted its position in shares of Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock worth $3,724,306,000 after purchasing an additional 7,157,113 shares during the last quarter. Pacer Advisors Inc. boosted its position in shares of Gilead Sciences by 723.3% in the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company's stock worth $594,370,000 after purchasing an additional 5,653,075 shares during the last quarter. Northern Trust Corp raised its stake in Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after buying an additional 2,458,954 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Gilead Sciences during the 4th quarter worth $207,340,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Down 1.3%

Shares of NASDAQ:GILD traded down $1.39 during midday trading on Wednesday, reaching $107.72. The company had a trading volume of 7,958,565 shares, compared to its average volume of 7,714,002. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. The business's 50 day moving average price is $105.44 and its 200 day moving average price is $100.07. The stock has a market cap of $134.00 billion, a PE ratio of 291.14, a P/E/G ratio of 0.71 and a beta of 0.26. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Gilead Sciences's quarterly revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.32) earnings per share. Research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.93%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio is currently 66.53%.

Wall Street Analysts Forecast Growth

GILD has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a "hold" rating to a "buy" rating and raised their price objective for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. BMO Capital Markets raised their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a research note on Wednesday. Wells Fargo & Company raised their price objective on Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Finally, Oppenheimer dropped their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Nine analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $110.55.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the completion of the transaction, the chief financial officer now owns 165,674 shares in the company, valued at approximately $16,537,578.68. This trade represents a 1.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last quarter, insiders have sold 22,929 shares of company stock valued at $2,634,220. 0.27% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.